Quick Answer
Neurogene Inc. reported Operating Income Loss of -$103.33 million for the year ending 2025.
- Neurogene Inc. showed a decrease of -25.1% in Operating Income Loss from 2024 to 2025.
- This data is from Neurogene Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$14.00 million | Q3 2017: -$12.07 million | Q2 2018: $2.69 million | Q3 2018: -$15.20 million | Q2 2019: -$428.0 thousand | Q3 2019: -$59.52 million | Q1 2020: -$9.07 million | Q2 2020: -$9.77 million | Q3 2020: -$2.25 million | Q1 2021: -$14.95 million | Q2 2021: -$15.12 million | Q3 2021: -$15.45 million | Q1 2022: -$15.37 million | Q2 2022: -$15.87 million | Q3 2022: -$13.61 million | Q1 2023: -$13.04 million | Q2 2023: -$12.60 million | Q3 2023: -$15.22 million | Q1 2024: -$18.78 million | Q2 2024: -$20.13 million | Q3 2024: -$22.18 million | Q1 2025: -$25.92 million | Q2 2025: -$26.08 million | Q3 2025: -$23.80 million.
- Over the full 10 years of available data (2016 to 2025), Neurogene Inc.'s Operating Income Loss has declined by 174.5%.
- Historical annual values: Fiscal year 2025: -$103.33 million | Fiscal year 2024: -$82.61 million | Fiscal year 2023: -$55.58 million | Fiscal year 2022: -$56.52 million | Fiscal year 2021: -$60.70 million | Fiscal year 2020: -$33.73 million | Fiscal year 2019: -$70.96 million | Fiscal year 2018: -$32.62 million | Fiscal year 2017: -$51.12 million | Fiscal year 2016: -$37.65 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: